Athenex Inc (NASDAQ:ATNX) Director Song-Yi Zhang sold 53,439 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $17.11, for a total value of $914,341.29. Following the completion of the transaction, the director now owns 4,000 shares of the company’s stock, valued at approximately $68,440. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Song-Yi Zhang also recently made the following trade(s):

  • On Friday, August 24th, Song-Yi Zhang sold 23,137 shares of Athenex stock. The shares were sold at an average price of $17.17, for a total value of $397,262.29.
  • On Wednesday, August 22nd, Song-Yi Zhang sold 102,734 shares of Athenex stock. The shares were sold at an average price of $17.24, for a total value of $1,771,134.16.
  • On Friday, August 17th, Song-Yi Zhang sold 70,133 shares of Athenex stock. The stock was sold at an average price of $17.18, for a total value of $1,204,884.94.
  • On Wednesday, August 15th, Song-Yi Zhang sold 43,845 shares of Athenex stock. The stock was sold at an average price of $16.53, for a total value of $724,757.85.

Shares of Athenex stock opened at $16.91 on Wednesday. Athenex Inc has a 1 year low of $13.28 and a 1 year high of $20.90.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.10). Athenex had a negative return on equity of 73.37% and a negative net margin of 122.29%. The firm had revenue of $11.57 million for the quarter. equities analysts predict that Athenex Inc will post -2 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Athenex by 426.5% during the 1st quarter. Barclays PLC now owns 5,913 shares of the company’s stock worth $100,000 after purchasing an additional 4,790 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Athenex by 363.2% during the 2nd quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after purchasing an additional 5,434 shares in the last quarter. KCS Wealth Advisory purchased a new stake in shares of Athenex during the 1st quarter worth about $179,000. Jane Street Group LLC purchased a new stake in shares of Athenex during the 1st quarter worth about $208,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Athenex during the 2nd quarter worth about $266,000. 19.82% of the stock is owned by institutional investors.

ATNX has been the subject of several research analyst reports. ValuEngine raised Athenex from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. BidaskClub downgraded Athenex from a “buy” rating to a “hold” rating in a research note on Saturday, May 26th. Finally, Zacks Investment Research downgraded Athenex from a “buy” rating to a “hold” rating in a research note on Wednesday, May 30th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Athenex has an average rating of “Hold” and an average target price of $26.71.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Featured Story: Growth Stocks

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.